Trial | NCT03132779  Report issue

Title

Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion
Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortions

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    34
Evaluating the effect of intralipid on the natural killer cells
This study will done on women with recurrent spontaneous abortions having increased NKCELLS activity and evaluate the effect of Intralipid on them after re-estimation of NKcells activity again after one week of Intralipid adminstration
Study Started
May 01
2017
Anticipated
Primary Completion
Jan 20
2018
Anticipated
Study Completion
Feb 20
2018
Anticipated
Last Update
Apr 28
2017

Drug Intralipid

Adose of intralipid given and rechecking NKcells activity

  • Other names: Intralipid 18 mg

One armed Experimental

One group of patient will take Intralipid for all

Criteria 

Inclusion Criteria:

All women icluded having recurrent spontaneous abortions equal or more than twice.
Alittle women having increased NKCELLS activity.

Exclusion Criteria:

Any other diseases causing miscarriage as autoimmune (lupus erythematosus or antiphospholipid antibodies syndrome )or endocrinopathy (diabetes mellitus, thyroid disorders and hyperprolactinaemia)or thrombophilia (factor v leiden mutation, protein c or s deficiency, prothrombin G20210A mutation, antithrombin III deficiency ) or abnormal karyotyping to one or both of parents or previous history of hormonal contraception or intrauterine device usage at last 3 months or any contraindications for intralipid usage.
No Results Posted